Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
OCX

OCX - Oncocyte Corp Stock Price, Fair Value and News

$6.89+0.32 (+4.87%)
Market Closed

8/100

OCX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

8/100

OCX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$5.31

Target 3M

$5.98

Target 6M

$5.64

OCX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OCX Price Action

Last 7 days

-1.8%

Last 30 days

12.0%

Last 90 days

-1.7%

Trailing 12 Months

224.4%

OCX RSI Chart

OCX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OCX Valuation

Market Cap

197.5M

Price/Earnings (Trailing)

-3.25

Price/Sales (Trailing)

44.87

EV/EBITDA

-4.23

Price/Free Cashflow

-8.25

OCX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$5.31

Target 3M

$5.98

Target 6M

$5.64

OCX Fundamentals

OCX Revenue

Revenue (TTM)

4.4M

Rev. Growth (Yr)

126.09%

Rev. Growth (Qtr)

-49.81%

OCX Earnings

Earnings (TTM)

-60.8M

Earnings Growth (Yr)

19.56%

Earnings Growth (Qtr)

-11.41%

OCX Profitability

Operating Margin

55.38%

EBT Margin

-907.38%

Return on Equity

-5.5K%

Return on Assets

-138.33%

Free Cashflow Yield

-12.12%

OCX Investor Care

Shares Dilution (1Y)

70.26%

Diluted EPS (TTM)

-3.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20253.8M4.3M4.4M0
20241.4M1.0M709.0K1.9M
20236.5M6.8M7.1M7.2M
20228.0M6.2M5.3M2.0M
20212.3M4.2M4.6M7.7M
2020524.0K755.0K986.0K1.2M
2017000293.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Oncocyte Corp

OCX
OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
 CEO
 WEBSITEhttps://oncocyte.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES75

Oncocyte Corp Frequently Asked Questions

OCX is the stock ticker symbol of Oncocyte Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jan 27 2026, market cap of Oncocyte Corp is 197.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check OCX's fair value in chart for subscribers.

The fair value guage provides a quick view whether OCX is over valued or under valued. Whether Oncocyte Corp is cheap or expensive depends on the assumptions which impact Oncocyte Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OCX.

As of Tue Jan 27 2026, OCX's PE ratio (Price to Earnings) is -3.25 and Price to Sales (PS) ratio is 44.87. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OCX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Oncocyte Corp has provided -0.189 (multiply by 100 for percentage) rate of return.